Avontec's products are based on a novel therapeutic concept that employs double-stranded DNA oligonucleotides, which act as decoys for transcription factors. Decoys imitate a promoter consensus DNA-binding site for transcription factors and thus effectively prohibit binding of the transcription factor to its natural gene control regions in a competitive manner.